Exploring potential anticoagulant drug formulations using thrombin generation test

Area of Science:

• Pharmacology
• Hematology
• Biochemistry

Background:

• Anticoagulant drugs target coagulation cascade proteins, primarily thrombin and factor Xa, to prevent thrombosis but risk increasing bleeding.
• Maintaining a balance between thrombosis and bleeding within a drug's therapeutic window is crucial for effective anticoagulation.

Purpose of the Study:

• To rank coagulation factors as potential targets for novel anticoagulant drugs, particularly in combination therapies.
• To evaluate promising dual-target strategies using thrombin inhibitors combined with other coagulation factor inhibitors.

Main Methods:

• Utilized the thrombin generation test to assess the entire coagulation cascade in normal and factor-deficient human blood plasma.
• Estimated potential therapeutic windows for various coagulation factors to rank their suitability as drug targets.

Main Results:

• Thrombin and factor Xa were confirmed as the most promising anticoagulant targets, aligning with current drug development.
• Inhibitors of factors Va and VIIa are predicted to have narrow therapeutic windows, while factors VIIIa and IXa inhibitors show moderate effects.
• Factors XI and XII were identified as poor targets for anticoagulant drug development.
• Thrombin inhibitors (bivalirudin, aptamer HD1) showed increased activity in factor II-deficient plasma.
• The most promising combinations involved anti-thrombin with anti-V/Va or anti-IX/IXa, demonstrating incremental dose-effect relationships.

Conclusions:

• Dual-target anticoagulant strategies, particularly combining thrombin inhibition with inhibition of factor V/Va or factor IX/IXa, offer promising therapeutic potential.
• The incremental dose-effect dependence observed in these combinations supports the feasibility of achieving a balanced therapeutic window.